Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELDORADO: Elranatamab vs Daratumumab with RVd Lite in Newly Diagnosed Multiple Myeloma
NCT07247097Phase 2Not yet recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2026
- Primary completion
- Dec 2030
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elranatamab in multiple myeloma (MM), sponsored by Massachusetts General Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07247097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07247097.